Efficacy and safety of different curcumin formulations in osteoarthritis: an umbrella review of systematic reviews.
- 2026-05-21
- Frontiers in medicine 13
- Chuankai Shi
- Taimin Zhang
- Yaru Xie
- Jiajia Li
- Changxu Chen
- Jiangwei Liu
- PubMed: 42254374
- DOI: 10.3389/fmed.2026.1801273
Study Design
- Type
- Systematic Review
- Methods
- Systematic search across PubMed, Web of Science, Cochrane, Embase, Scopus, and MEDLINE up to September 2025
Background
This umbrella review synthesizes evidence from systematic reviews and meta-analyses evaluating the efficacy and safety of diverse curcumin formulations in the treatment of osteoarthritis (OA). The objective is to assess curcumin's therapeutic potential and inform future formulation development.Methods
A systematic search was conducted across PubMed, Web of Science, Cochrane, Embase, Scopus, and MEDLINE up to September 2025 to identify systematic reviews and meta-analyses investigating curcumin for OA (requiring at least one randomized controlled trial). Methodological quality was assessed using AMSTAR-2. Due to limited data and substantial heterogeneity in formulations and study designs, findings were synthesized qualitatively.Results
Ten meta-analyses and systematic reviews were included. Curcumin formulations exhibited significant improvements in pain (VAS) and joint function/stiffness (WOMAC), showing efficacy signals comparable to non-steroidal anti-inflammatory drugs (NSAIDs) and a more favorable tolerability profile in the available studies. However, methodological and clinical heterogeneity was substantial (AMSTAR-2 rated only three studies as high quality). Variations in curcumin composition, bioavailability-enhancing strategies, and extraction methods, coupled with the absence of direct comparative analyses among formulations, precluded definitive inter-group comparisons.Conclusion
Curcumin-based interventions show promise for OA symptom management, with efficacy signals comparable to NSAIDs and appear to have a more favorable tolerability profile in the available studies, while addressing bioavailability challenges. Nevertheless, pronounced heterogeneity and the lack of head-to-head comparative studies, and incomplete safety reporting across reviews preclude definitive conclusions regarding superiority over NSAIDs or optimal formulations, and formulation-specific inferences remain limited. Future research should prioritize high-quality comparative trials or network meta-analyses to confirm efficacy signals and enable formulation-specific inferences.Systematic review registration
https://www.crd.york.ac.uk/PROSPERO, identifier CRD420251172722.Research Insights
Curcumin formulations exhibited significant improvements in pain (VAS) and joint function/stiffness (WOMAC), showing efficacy signals comparable to non-steroidal anti-inflammatory drugs (NSAIDs)
- Effect
- Beneficial
- Effect size
- Moderate
Curcumin formulations exhibited significant improvements in pain (VAS) and joint function/stiffness (WOMAC), showing efficacy signals comparable to non-steroidal anti-inflammatory drugs (NSAIDs)
- Effect
- Beneficial
- Effect size
- Moderate
Curcumin formulations exhibited significant improvements in pain (VAS) and joint function/stiffness (WOMAC), showing efficacy signals comparable to non-steroidal anti-inflammatory drugs (NSAIDs)
- Effect
- Beneficial
- Effect size
- Moderate
Adverse Events Reported
Curcumin formulations exhibited significant improvements in pain (VAS) and joint function/stiffness (WOMAC), showing efficacy signals comparable to non-steroidal anti-inflammatory drugs (NSAIDs) and a more favorable tolerability profile in the available studies.
- Finding
- Reported